224 related articles for article (PubMed ID: 37259024)
21. Cloning of thrombopoietin and its therapeutic potential.
Miyazaki H
Cancer Chemother Pharmacol; 1996; 38 Suppl():S74-7. PubMed ID: 8765422
[TBL] [Abstract][Full Text] [Related]
22. The role of platelet factor 4 in radiation-induced thrombocytopenia.
Lambert MP; Xiao L; Nguyen Y; Kowalska MA; Poncz M
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1533-40. PubMed ID: 21740995
[TBL] [Abstract][Full Text] [Related]
23. Megakaryocyte growth and development factor (MGDF): an Mpl ligand and cytokine that regulates thrombopoiesis.
Neumann TA; Foote M
Cytokines Cell Mol Ther; 2000 Mar; 6(1):47-56. PubMed ID: 10976539
[TBL] [Abstract][Full Text] [Related]
24. Recombinant human ligand for MPL, megakaryocyte growth and development factor (MGDF), stimulates thrombopoiesis in vivo in normal and myelosuppressed baboons.
Andrews RG; Winkler A; Myerson D; Briddell RA; Knitter GH; McNiece IK; Hunt P
Stem Cells; 1996 Nov; 14(6):661-77. PubMed ID: 8948024
[TBL] [Abstract][Full Text] [Related]
25. Thrombopoietin stimulates colony-forming unit-megakaryocyte proliferation and megakaryocyte maturation independently of cytokines that signal through the gp130 receptor subunit.
Broudy VC; Lin NL; Fox N; Taga T; Saito M; Kaushansky K
Blood; 1996 Sep; 88(6):2026-32. PubMed ID: 8822921
[TBL] [Abstract][Full Text] [Related]
26. Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.
Harker LA; Marzec UM; Hunt P; Kelly AB; Tomer A; Cheung E; Hanson SR; Stead RB
Blood; 1996 Jul; 88(2):511-21. PubMed ID: 8695799
[TBL] [Abstract][Full Text] [Related]
27. Erythropoietin is a major regulator of thrombopoiesis in thrombopoietin-dependent and -independent contexts.
Hacein-Bey-Abina S; Estienne M; Bessoles S; Echchakir H; Pederzoli-Ribeil M; Chiron A; Aldaz-Carroll L; Leducq V; Zhang Y; Souyri M; Louache F; Abina AM
Exp Hematol; 2020 Aug; 88():15-27. PubMed ID: 32721504
[TBL] [Abstract][Full Text] [Related]
28. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer.
Vadhan-Raj S; Murray LJ; Bueso-Ramos C; Patel S; Reddy SP; Hoots WK; Johnston T; Papadopolous NE; Hittelman WN; Johnston DA; Yang TA; Paton VE; Cohen RL; Hellmann SD; Benjamin RS; Broxmeyer HE
Ann Intern Med; 1997 May; 126(9):673-81. PubMed ID: 9139552
[TBL] [Abstract][Full Text] [Related]
29. Romiplostim for management of chemotherapy-induced thrombocytopenia.
Parameswaran R; Lunning M; Mantha S; Devlin S; Hamilton A; Schwartz G; Soff G
Support Care Cancer; 2014 May; 22(5):1217-22. PubMed ID: 24414994
[TBL] [Abstract][Full Text] [Related]
30. Sequential administration of the high affinity CXCR4 antagonist BKT140 promotes megakaryopoiesis and platelet production.
Abraham M; Weiss ID; Wald H; Wald O; Nagler A; Beider K; Eizenberg O; Peled A
Br J Haematol; 2013 Oct; 163(2):248-59. PubMed ID: 23906028
[TBL] [Abstract][Full Text] [Related]
31. Managing thrombocytopenia associated with cancer chemotherapy.
Kuter DJ
Oncology (Williston Park); 2015 Apr; 29(4):282-94. PubMed ID: 25952492
[TBL] [Abstract][Full Text] [Related]
32. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study.
Wolff SN; Herzig R; Lynch J; Ericson SG; Greer JP; Stein R; Goodman S; Benyunes MC; Ashby M; Jones DV; Fay J
Bone Marrow Transplant; 2001 Feb; 27(3):261-8. PubMed ID: 11277173
[TBL] [Abstract][Full Text] [Related]
33. Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice.
Akahori H; Shibuya K; Ozai M; Ida M; Kabaya K; Kato T; Miyazaki H
Stem Cells; 1996 Nov; 14(6):678-89. PubMed ID: 8948025
[TBL] [Abstract][Full Text] [Related]
34. Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl.
Yoshida H; Yamada H; Nogami W; Dohi K; Kurino-Yamada T; Sugiyama K; Takahashi K; Gahara Y; Kitaura M; Hasegawa M; Oshima I; Kuwabara K
Exp Hematol; 2018 Mar; 59():30-39.e2. PubMed ID: 29274361
[TBL] [Abstract][Full Text] [Related]
35. Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis.
Murray LJ; Luens KM; Estrada MF; Bruno E; Hoffman R; Cohen RL; Ashby MA; Vadhan-Raj S
Exp Hematol; 1998 Mar; 26(3):207-16. PubMed ID: 9502616
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice.
Krzyzanski W; Perez-Ruixo JJ; Harrold J
J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):709-20. PubMed ID: 26341875
[TBL] [Abstract][Full Text] [Related]
37. Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.
Soff GA; Miao Y; Bendheim G; Batista J; Mones JV; Parameswaran R; Wilkins CR; Devlin SM; Abou-Alfa GK; Cercek A; Kemeny NE; Sarasohn DM; Mantha S
J Clin Oncol; 2019 Nov; 37(31):2892-2898. PubMed ID: 31545663
[TBL] [Abstract][Full Text] [Related]
38. Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.
Al-Samkari H
Blood Rev; 2024 Jan; 63():101139. PubMed ID: 37914568
[TBL] [Abstract][Full Text] [Related]
39. Thrombocytopenic c-mpl(-/-) mice can produce a normal level of platelets after administration of 5-fluorouracil: the effect of age on the response.
Levin J; Cocault L; Demerens C; Challier C; Pauchard M; Caen J; Souyri M
Blood; 2001 Aug; 98(4):1019-27. PubMed ID: 11493447
[TBL] [Abstract][Full Text] [Related]
40. Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease.
Michelson AD; Smolensky Koganov E; Forde EE; Carmichael SL; Frelinger AL
J Thromb Haemost; 2018 Dec; 16(12):2515-2519. PubMed ID: 30264918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
